



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

			URGEN	
MEMBER INFORMATION				
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:	DATE OF BIRTH:	
STREET ADDRESS:				
CITY:		STATE: ZIP CO	DDE:	
PATIENT INSURANCE ID	NUMBER:			
MALE FEMALE	HEIGHT (IN/CM): W	EIGHT (LB/KG): ALLE	ERGIES:	
		DISCLOSURE AUTHORIZATION FORM WITH THI OMMON/DOC/EN-US/PHI_DISCLOSURE_AUTH		
		BLE):		
PRESCRIBER INFORMATI	ON			
LAST NAME:		FIRST NAME:	FIRST NAME:	
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:	EMAIL ADDRESS:	
NPI NUMBER:		DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:	FAX NUMBER:	
STREET ADDRESS:				
CITY:		STATE: ZIP CO	DDE:	
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSO	OFFICE CONTACT PERSON:	
		1		
MEDICATION OR MEDIC	AL DISPENSING INFORMATIO	N		
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:	
NEW THERAPY RENEWAL DURATION OF THERAPY (SPECIFIC DATES):		IF RENEWAL: DATE THER	IF RENEWAL: DATE THERAPY INITIATED:	
Continued on next page.				

© 2017 – 2023 by Magellan Rx Management, LLC. All Rights Reserved.

Revision Date: 2.1.2023

CAT0007









Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:		
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO	
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:	
2. LIST DIAGNOSES:		ICD-10:	
□ Pulmonary arterial hypertension (PAH) □ Raynaud's phenomenon □ DiagnosisICD-10 Code(s)	:		
3. REQUIRED CLINICAL INFORMATION: PRIOR AUTHORIZATION.	: PLEASE PROVIDE ALL RELEVANT CLINICA	AL INFORMATION TO SUPPORT A	
Select if the diagnosis of Group 1 pulmetiologies:* Chronic hemolytic anemia	Group 1 pulmonary arterial hypertension nonary arterial hypertension (PAH) is car		
☐ Congenital heart disease(e.g. atrial-s	septal defect)		
 □ Associated with surgical repair of a control ventricular septal defect, patent ducture 	congenital systemic-to-pulmonary shun is arteriosus)	t of at least 1year in duration(e.g.,	
treatment) □ HIV infection □ Idiopathic/primary PAH □ Portal hypertension □ Schistosomiasis	ive to acute vasoreactivity testing(AVT) cleroderma, systemic sclerosis, CREST system		
Does the patient have WHO functiona *Please provide documentation.	I class II, III, or IV?* □ Yes □ No		
Is patient's diagnosis confirmed by car	rdiac catheterization?		
1	l by cardiac catheterization a mean puln h to confirm PAH? □ Yes □ No *Please		
	l by cardiac catheterization a pulmonary confirm PAH? □ Yes □ No *Please pro		
1	I by cardiac catheterization a pulmonary ght heart cath to confirm PAH? Yes		

© 2017 – 2023 by Magellan Rx Management, LLC. All Rights Reserved.

Revision Date: 2.1.2023

CAT0007









Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

If patient has idiopathic PAH, hereditaryPAH(excludes congenital heart disease like atrial=septal defect) or drug/toxin induced PAH, did patient have had an acute vasoreactivity test? Yes No *Please provide documentation.
Has patient been previously treated with a Calcium channel blocker? ☐ Yes ☐ No *Please provide documentation.
Select the prescribing physician's specialty: □ Cardiology □ Nephrology □ Pulmonology □ Rheumatology
Does patient have a history of left-sided heart disease? ☐ Yes ☐ No
Does patient have severe renal insufficiency? □ Yes □ No
Does patient have pulmonary hypertension related to conditions other than previously specified? ☐ Yes ☐ No
For Raynaud's phenomenon, answer the following:
Is the prescribing physician a rheumatologist? ☐ Yes ☐ No
Is the patient's Raynaud's phenomenon secondary to systemic sclerosis/scleroderma?* — Yes — No *Please provide documentation.
Has the patient received prior treatment with, and is intolerant of or resistant to, at least one calcium channel blocker?* Yes No *Please provide documentation.
Will the patient be using a calcium channel blocker on alternate days with Adcirca? ☐ Yes ☐ No
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?
Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.
ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.
Prescriber Signature or Electronic I.D. Verification:
CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents

© 2017 – 2023 by Magellan Rx Management, LLC. All Rights Reserved.

Revision Date: 2.1.2023

CAT0007









Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811



Revision Date: 2.1.2023

CAT0007

Page 4 of 4



